NCT00288431已完成1 期
A Phase 1B, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 37
- 主要终点
- determine the maximum tolerated dose (MTD) of oral AP23573 in combination with doxorubicin
研究概览
简要总结
This study is designed to determine the safety, tolerability and maximum tolerated dose of Oral AP23573 in combination with Doxorubicin
详细描述
The primary objective is to determine the maximum tolerated dose (MTD) of AP23573 in combination with doxorubicin, to characterize the safety profile of AP23573 in combination with doxorubicin, and to examine the pharmacokinetics of AP23573 and doxorubicin when given in combination to patients with advanced malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years with a histological/cytological diagnosis of advanced tumor, preferentially breast, sarcoma, ovarian, endometrial or other tumor types for which treatment with anthracycline therapy is indicated
- •Prior cumulative doxorubicin exposure less than 400 mg/m2
- •An ECOG performance status of 0 or 1
- •Adequate cardiovascular function
- •Measurable disease according to modified RECIST criteria
- •Adequate hematological, renal and hepatic functions
- •Able to understand and give voluntary written informed consent
排除标准
- •Women who are pregnant or lactating
- •Presence of active brain metastases. Patients with treated brain metastases will be eligible if they are on a stable dose of corticosteroids or are without change in brain disease status for at least 4 weeks following related therapy (e.g., whole brain radiation, surgery)
- •Prior treatment with CCI-779, rapamycin, or any other mTOR inhibitor
- •Prior anticancer treatment (chemotherapy, radiotherapy, hormonal, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of AP23573; the interval is ≥ 2 weeks for signal transduction inhibitors with a half-life known to be <24 hours, and is ≥ 6 weeks for nitrosourea or mitomycin. Exception: Concurrent treatment with LHRH agonists is allowed for patients with prostate cancer.
- •Ongoing toxicity associated with prior anticancer therapy other than alopecia and ≤ Grade 1 peripheral neuropathy by NCI toxicity criteria
- •Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)
- •Known or suspected hypersensitivity to any excipient contained in the study drug
- •Known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin)
- •Significant uncontrolled cardiovascular disease
- •Any active infection requiring prescribed intervention
- •Any other concurrent illness which, in the opinion of the investigator, would either compromise the patient's safety or interfere with the evaluation of the safety of the study drug
- •Any pre-existing malabsorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption
- •Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids at stable doses for ≥ 2 weeks prior to first planned dose of study drug
- •Concurrent treatment with medications that induce or inhibit cytochrome P450 (CYP3A)
- •Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of AP23573
研究组 & 干预措施
1
Experimental
Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
干预措施: ridaforolimus (Drug)
1
Experimental
Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
干预措施: Doxorubicin (Drug)
结局指标
主要结局
determine the maximum tolerated dose (MTD) of oral AP23573 in combination with doxorubicin
时间窗: Duration of study
次要结局
- Describe the antitumor activity of the study drug combination for each dosing schedule(Duration of study)
- examine the pharmacokinetics of oral AP23573 and doxorubicin when given in combination(Duration of study)
- Examine pharmacodynamic characteristics of AP23573 for those patients enrolled into the expanded MTD cohorts only(Duration of study)
研究者
相似试验
已完成
1 期
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)TumorsMultiple MyelomaLymphomaNCT00060645Merck Sharp & Dohme LLC33
已完成
1 期
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)Malignant GliomaGliosarcomaGlioblastomaNCT00087451Merck Sharp & Dohme LLC11
终止
1 期
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDSAcute Myelogenous Leukemia in RelapseAcute Myelogenous Leukemia, Relapsed, AdultAcute Myelogenous Leukemia, AdultAcute Myelogenous LeukemiaHigh Risk MyelodysplasiaNCT02267863Aptose Biosciences Inc.21
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male SubjectsHealthy VolunteersPharmacokinetics of ASP3700NCT02155504Astellas Pharma Europe B.V.44
已完成
1 期
A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CChronic Hepatitis C InfectionGenotype 1NCT01194037HanAll BioPharma Co., Ltd.30